FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 142 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Singer Rebecca Crews, Wife Of Terry Crews, Diagnosed With Breast Cancer... April 13, 2020 How NatWest Group are making a difference this Giving Tuesday November 29, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Amivantamab October 29, 2021 ‘Levelling Up’: What should it mean for cancer? February 2, 2022 Load more HOT NEWS Patients With DCIS Reduce Risk Of Recurrence And Death If They... Keto Molecule Offers Clue for Preventing Colorectal Cancer Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer Does Too Much Fructose Help Colorectal Cancers Grow?
